Allograft Survival with Iloprost
Short-term cardiac allograft survival has improved substantially since the introduction of cyclosporin A (CsA). However, death from coronary atherosclerosis resulting form chronic rejection is now the major problem; clearly CsA does not provide adequate long-term allograft protection and, in addition, possesses a number of undesirable side effects including renal toxicity which is particularly prominent in cardiac transplant patients where some of the patients are now placed on chronic hemodialysis. The combination of prednisone with CsA seems superior to CsA alone in promoting allograft survival. However, treatment with prednisone is also linked to serious short-term side effects including bone necrosis and cataract.
KeywordsGraft Survival Cardiac Allograft Allograft Survival Cardiac Transplant Patient Cardiac Allograft Survival
Unable to display preview. Download preview PDF.
- 2.Foegh ML, Alijani MR, Helfrich GB, Khirabadi BS, Goldman MH, Lower RR, Ramwell PW (1985) Thromboxane and leukotrienes in clinical and experimental transplant rejection. Adv Prostaglandin Thromboxane Leukotriene Res, vol 8, 13: 209–217Google Scholar
- 5.Jamieson SW, Burton N, Reitz B (1979) Platelets sulfinpyrazone and organ graft rejection. In: McGregor M, Mustard J, Oliver M, Sherry S (1979) Cardiovascular actions of sulfin-pyrazone: basic and clinical research. Symposia Specialist, Miami, pp 329–243Google Scholar
- 7.Kort WJ, Bonta IL, Adolfs MJP, Westbrook DL (1982) Synergism of (15S-)-15-methyl-prostaglandin E with either azathioprine or prednisolone on the survival of hearts allografts in rats. Prostaglandin Thromboxane Leukotriene Med 8: 661–664Google Scholar
- 11.Ono K, Lindsey ES (1969) Improved technique of heart transplantation in rats. J Thorac Cardiovasc Surg 57: 255–259Google Scholar
- 17.Zao HX, Aziz S, Kasahara K, Billingham ME, Jamieson SW, Stinson EB, Shumway NE (1984) Improved immunosuppression using cyclosporine with 15-methyl prostaglandin E1. Surg Forum 35: 382–384Google Scholar